FR24C1008I1 - Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire - Google Patents

Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire

Info

Publication number
FR24C1008I1
FR24C1008I1 FR24C1008C FR24C1008C FR24C1008I1 FR 24C1008 I1 FR24C1008 I1 FR 24C1008I1 FR 24C1008 C FR24C1008 C FR 24C1008C FR 24C1008 C FR24C1008 C FR 24C1008C FR 24C1008 I1 FR24C1008 I1 FR 24C1008I1
Authority
FR
France
Prior art keywords
antibodies against
tissue factor
pathway inhibitor
against tissue
factor pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1008C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40639722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1008(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of FR24C1008I1 publication Critical patent/FR24C1008I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR24C1008C 2008-12-22 2024-02-26 Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire Active FR24C1008I1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08172520 2008-12-22
EP09793543.1A EP2379600B2 (en) 2008-12-22 2009-12-18 Antibodies against tissue factor pathway inhibitor
PCT/EP2009/067598 WO2010072691A1 (en) 2008-12-22 2009-12-18 Antibodies against tissue factor pathway inhibitor

Publications (1)

Publication Number Publication Date
FR24C1008I1 true FR24C1008I1 (fr) 2024-04-19

Family

ID=40639722

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1008C Active FR24C1008I1 (fr) 2008-12-22 2024-02-26 Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire

Country Status (19)

Country Link
US (5) US8361469B2 (es)
EP (3) EP2379600B2 (es)
JP (2) JP5714505B2 (es)
KR (2) KR101600308B1 (es)
CN (1) CN102325795B (es)
AU (1) AU2009331570C1 (es)
BR (1) BRPI0924058B1 (es)
CA (1) CA2745317C (es)
DK (1) DK2379600T4 (es)
ES (1) ES2458665T5 (es)
FR (1) FR24C1008I1 (es)
IL (1) IL213356A (es)
MX (1) MX2011006501A (es)
PL (1) PL2379600T5 (es)
PT (1) PT2379600E (es)
RU (1) RU2562114C2 (es)
TW (1) TWI476003B (es)
WO (1) WO2010072691A1 (es)
ZA (1) ZA201104599B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010000721A1 (en) 2008-06-30 2010-01-07 Novo Nordisk A/S Anti-human interleukin-20 antibodies
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
DK2379600T4 (da) * 2008-12-22 2021-01-04 Novo Nordisk As Antistoffer mod tissue factor pathway inhibitor
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
US9795674B2 (en) * 2010-02-26 2017-10-24 Novo Nordisk A/S Stable antibody containing compositions
NZ702494A (en) 2010-03-01 2016-09-30 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
WO2012001087A1 (en) 2010-06-30 2012-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
MY165499A (en) * 2011-04-01 2018-03-27 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014144689A1 (en) * 2013-03-15 2014-09-18 Bayer Healthcare Llc Pro-drug antibodies against tissue factor pathway inhibitor
JP6586016B2 (ja) * 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
RS56814B1 (sr) * 2013-03-15 2018-04-30 Bayer Healthcare Llc Varijante anti-tfpi antitela sa diferencijalnim vezivanjem duž ph opsega zarad poboljšanja farmakokinetike
US10457743B2 (en) 2013-07-19 2019-10-29 Novo Nordisk A/S Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
EP3036005A4 (en) 2013-08-21 2017-04-26 The Board Of Regents Of The University Of Texas System Compositions and methods for targeting connexin hemichannels
JP6502959B2 (ja) * 2013-12-12 2019-04-17 上海恒瑞医薬有限公司 Ｐｄ−１抗体、その抗原結合性断片及びそれらの医学的使用
AP2016009564A0 (en) * 2014-04-27 2016-11-30 Ccam Biotherapeutics Ltd Humanized antibodies against ceacam1
CN106687482B (zh) * 2014-09-17 2022-01-25 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
MY178445A (en) * 2015-02-25 2020-10-13 Mogam Inst Biomedical Res Novel antibody binding to tfpi and composition comprising the same
RU2705540C2 (ru) * 2015-08-19 2019-11-07 Пфайзер Инк. Антитела против ингибитора пути тканевого фактора и их применения
JP7098527B2 (ja) 2016-02-26 2022-07-11 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム コネキシン（Ｃｘ）４３ヘミチャネル結合抗体及びその使用
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TWI788321B (zh) * 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
JP7094722B2 (ja) * 2018-02-28 2022-07-04 キヤノン株式会社 画像読取装置及び画像形成装置
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
AU2019359540B2 (en) * 2018-10-11 2024-07-11 Pfizer Inc. Dosage regimen for TFPI antagonists
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
KR20220100634A (ko) * 2019-11-13 2022-07-15 화이자 인코포레이티드 안정한 수성 항-tfpi 항체 제제
US20230220111A1 (en) * 2020-07-02 2023-07-13 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN116390715A (zh) 2020-09-24 2023-07-04 诺和诺德医疗保健公司 康赛珠单抗的药物制剂及其制备方法
WO2023143559A1 (en) * 2022-01-30 2023-08-03 Westlake University Tfpi binding polypeptides and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966852A (en) † 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
EP0539975A1 (en) † 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
JPH06153981A (ja) 1992-11-30 1994-06-03 Teijin Ltd Ｌａｃｉの免疫学的測定方法、それに用いるキット並びにモノクローナル抗体
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JPH0875736A (ja) 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
JP4187277B2 (ja) 1997-04-30 2008-11-26 エンゾン ファーマシューティカルズ， インコーポレイテッド グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用
EP1265928B1 (en) * 2000-01-27 2010-07-21 Medimmune, LLC Ultra high affinity rsv neutralizing antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
US7585842B2 (en) 2004-04-16 2009-09-08 The Reagents Of The University Of California Human kunitz-type inhibitor with enhanced antifibrinolytic activity
US7015746B1 (en) * 2004-05-06 2006-03-21 National Semiconductor Corporation Bootstrapped bias mixer with soft start POR
ATE505488T1 (de) † 2005-03-04 2011-04-15 Univ Illinois Modulator von coagulationskaskaden und fibrinolytischen kaskaden
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2010071894A2 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Tfpi inhibitors and methods of use
JP5791512B2 (ja) * 2008-12-22 2015-10-07 ノヴォ ノルディスク アー／エス 組織因子経路阻害因子（ｔｆｐｉ）に対する抗体
DK2379600T4 (da) * 2008-12-22 2021-01-04 Novo Nordisk As Antistoffer mod tissue factor pathway inhibitor
US8965454B2 (en) 2009-03-04 2015-02-24 Andrew Llc Amplifier system for cell sites and other suitable applications
CN102869385A (zh) 2009-08-18 2013-01-09 巴克斯特国际公司 针对组织因子途径抑制物的适体和其作为出血病症治疗剂的用途
US8598327B2 (en) 2009-08-18 2013-12-03 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
NZ702494A (en) * 2010-03-01 2016-09-30 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US8598008B2 (en) † 2010-10-20 2013-12-03 Texas Instruments Incorporated Stacked ESD clamp with reduced variation in clamp voltage
WO2012109675A1 (en) † 2011-02-11 2012-08-16 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
MY165499A (en) † 2011-04-01 2018-03-27 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
AU2013235567A1 (en) † 2012-03-22 2014-10-09 Baxalta GmbH Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
JP6586016B2 (ja) 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
MY178445A (en) † 2015-02-25 2020-10-13 Mogam Inst Biomedical Res Novel antibody binding to tfpi and composition comprising the same
RU2705540C2 (ru) † 2015-08-19 2019-11-07 Пфайзер Инк. Антитела против ингибитора пути тканевого фактора и их применения

Also Published As

Publication number Publication date
ES2458665T5 (es) 2021-06-30
DK2379600T4 (da) 2021-01-04
AU2009331570B2 (en) 2013-10-17
JP2015178495A (ja) 2015-10-08
ZA201104599B (en) 2012-03-28
JP5714505B2 (ja) 2015-05-07
JP6114326B2 (ja) 2017-04-12
KR101600308B1 (ko) 2016-03-07
IL213356A0 (en) 2011-07-31
KR20110103432A (ko) 2011-09-20
US9574011B2 (en) 2017-02-21
EP2746294A3 (en) 2015-01-07
KR101745394B1 (ko) 2017-06-09
CA2745317C (en) 2019-03-05
US8361469B2 (en) 2013-01-29
EP2379600B2 (en) 2020-10-14
AU2009331570A1 (en) 2011-06-30
PT2379600E (pt) 2014-04-29
MX2011006501A (es) 2011-07-12
US8652471B2 (en) 2014-02-18
US20130251722A1 (en) 2013-09-26
CN102325795A (zh) 2012-01-18
AU2009331570C1 (en) 2024-04-18
CN102325795B (zh) 2015-03-25
WO2010072691A1 (en) 2010-07-01
BRPI0924058B1 (pt) 2021-08-17
DK2379600T3 (da) 2014-04-28
PL2379600T5 (pl) 2021-03-08
RU2562114C2 (ru) 2015-09-10
KR20160031028A (ko) 2016-03-21
EP2379600A1 (en) 2011-10-26
US20130251721A1 (en) 2013-09-26
US20190211112A1 (en) 2019-07-11
EP3260466A1 (en) 2017-12-27
BRPI0924058A2 (pt) 2019-10-15
TWI476003B (zh) 2015-03-11
PL2379600T3 (pl) 2014-07-31
TW201026330A (en) 2010-07-16
US20170114147A1 (en) 2017-04-27
CA2745317A1 (en) 2010-07-01
US20110318356A1 (en) 2011-12-29
JP2012513377A (ja) 2012-06-14
EP2746294A2 (en) 2014-06-25
RU2011129068A (ru) 2013-01-27
EP2379600B1 (en) 2014-01-22
ES2458665T3 (es) 2014-05-06
IL213356A (en) 2017-06-29

Similar Documents

Publication Publication Date Title
FR24C1008I1 (fr) Anticorps dirigés contre l'inhibiteur de la voie du facteur tissulaire
FR17C1022I2 (fr) Anticorps humains à grande affinité contre pcsk9
ES2590905T8 (es) Inhibidores de la tirosina quinasa de Bruton
BRPI0906025A2 (pt) "aparelho de refrigeração"
BRPI0906085A2 (pt) "aparelho de refrigeração"
BRPI1010909A2 (pt) "inseticida arilpirrolinas"
BRPI0907890A2 (pt) Implantes lacrimais e métodos relacionados
ITTO20080027U1 (it) "apparato di refrigerazione domestico"
BRPI1013015A2 (pt) "osteosíntese com nanoprata"
FR2908035B1 (fr) Implant interepineux
BRPI0914533A2 (pt) "métodos"
BRPI0819960A2 (pt) "biomaterial e método de preparação do mesmo"
FR2932680B1 (fr) Association de tiliroside et d'un peptide
FI20065482A0 (fi) Vuodesohva
MA30860B1 (fr) Myrtillier denomme "c97-390"
FR2929850B1 (fr) Inhibiteurs de l'enzyme tyrosinage
BRPI0906053A2 (pt) "enzima artificial"
BRPI0910484A2 (pt) esqueletos artificiais de proteína
FR2937246B1 (fr) Tetine hygienique
UA18085S (uk) Шафа спеціальна хірургів для білизни та взуття
TH104914B (th) "ตู้เย็น"
TH100014B (th) "ตู้เย็น"
EE200600022A (et) Varvaste ravi-proflaktiline separaator
TH96258B (th) "แม่เหล็กติดตู้เย็น"
FR2925857B1 (fr) Implant femoral